



Professor Sir Peter Horby, Professor Sir Martin Landray  
RECOVERY trial Co-chairs  
Nuffield Department of Population Health  
Oxford

5<sup>th</sup> November 2021

Dear Peter and Martin

**RECOVERY trial DMC report**

We reviewed the RECOVERY trial safety and efficacy data that were available today for the 44,431 patients randomised; that total includes 98 women who were pregnant at entry and 316 children.

For the interventions still in active recruitment, the numbers of adults included in the comparison of each agent with its control were respectively: baricitinib (6,920), dimethyl fumarate (652), high dose steroids (698) and empagliflozin (1,690).

The numbers of children included in the comparison of each agent with its control were: tocilizumab (55), anakinra (21) and baricitinib (26).

In the light of the available trial data and all relevant external information, we saw no cogent reason to modify the protocol or intake to the study.

The full DMC will next meet to review the safety and efficacy data for all treatments on 14<sup>th</sup> January 2022, with a Chairman's review on 10<sup>th</sup> December 2021.

Yours sincerely

Professor Peter Sandercock, MA, DM, FRCPE, FESO, FWSO  
Chairman RECOVERY trial DMC  
Emeritus Professor of Medical Neurology, Centre for Clinical Brain Sciences

Cc DMC members, RECOVERY trial office.

CENTRE DIRECTOR Professor S Chandran  
Professor M Dennis Professor A Farrall Professor S Grant Professor J Ironside Professor R Knight Professor S Lawrie  
Professor A McIntosh Professor M Macleod Professor I Marshall Professor D Owens Professor C Ritchie Professor P Sandercock  
Professor R Sellar Professor C Smith Professor C Sudlow Professor L Thomson Professor A Waldman Professor J Wardlaw Professor R Will

The University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK  
t: +44 (0)131 465 9602 / w: [www.ccbs.ed.ac.uk](http://www.ccbs.ed.ac.uk) / e: [Peter.sandercock@ed.ac.uk](mailto:Peter.sandercock@ed.ac.uk)